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Abstract
Background: Recently, a large group of patients with persistent dyspnea, poor physical capacity, and reduced
health-related quality of life (HRQoL) following pulmonary embolism (PE) has been identified and clustered under
the name “post pulmonary embolism syndrome” (PPS). These patients seem good candidates for pulmonary
rehabilitation. The aim of the study is to explore whether a pulmonary rehabilitation program can improve physical
capacity, dyspnea, and HRQoL in PPS patients.
Methods: A two-center randomized controlled trial (RCT) is being performed at Østfold Hospital and Akershus
University Hospital in Norway. Patients with PPS are 1:1 randomized into an intervention or a control group. The
intervention consists of a supervised, outpatient rehabilitation program twice weekly (1 h) for 8 weeks provided by
experienced physiotherapists. The intervention involves individually adapted exercises based on existing pulmonary
rehabilitation programs (relaxation, interval, and resistance training), and an educational session including topics
such as normal anatomy and physiology of the respiratory and circulatory system, information on PE/PPS, breathing
strategies, and benefits of exercise/physical activity. Patients randomized to the control group receive usual care
without specific instructions to exercise.
Participants in the intervention and control groups will be compared based on assessments conducted at baseline,
12 weeks, and 36 weeks after inclusion using the incremental shuttle walk test (primary outcome) and endurance
shuttle walk test (exercise capacity), Sensewear activity monitor (daily physical activity), the modified Medical
Research Council scale, the Shortness of Breath Questionnaire (dyspnea), and EQ-5D-5L and the Pulmonary
Embolism Quality of Life Questionnaire (HRQoL).
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Recruitment of 190 patients is currently ongoing.
Discussion: Results from this study may provide a currently untreated group of PPS patients with an effective
treatment resulting in reduced symptoms of dyspnea, improved exercise capacity, and better HRQoL following PE.
Trial registration: Clinical Trials NCT03405480. Registered prospectively on September 2017.
Protocol version 1 (from original protocol September 2017).
The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for
Clinical Interventional Trials (SPIRIT) guidelines (Additional file 1).
Keywords: Pulmonary embolism, Rrehabilitation, Dyspnea, Exercise capacity, Quality of life, Randomized controlled
trial
Background
Pulmonary embolism (PE) occurs when an emboli blocks
a pulmonary artery resulting in acute symptoms, such as
dyspnea and chest pain, which usually subside gradually
with the majority of patients regaining normal function
within 3–6months [1]. However, long-term complications
following PE can include recurrent venous thrombo-
embolism (VTE), bleeding, and chronic thromboembolic
pulmonary hypertension (CTEPH) [2, 3].
Several studies have shown that up to 50% of patients
complain of various grades of persistent unexplained
dyspnea many years after the diagnosis of PE [4, 5]. Fur-
thermore, patients who reported dyspnea had reduced
exercise capacity as measured by the 6-min walk test
(6MWT) compared to patients with no dyspnea [6].
Additionally, those suffering from persistent dyspnea
had impaired health-related quality of life (HRQoL)
compared to both the normative population and PE pa-
tients without dyspnea [4]. These findings have recently
been confirmed by a prospective study showing that half
of PE patients have an exercise limitation at 1 year post-
PE which negatively influences walking distance and re-
duces HRQoL [7]. Some of these patients have persistent
pathological findings, such as right ventricular dysfunc-
tion, pulmonary hypertension, or residual perfusion de-
fects causing dead space ventilation, which may explain,
at least in part, the persistent symptoms. The majority of
patients, however, have no detectable cardiopulmonary
sequel and merely suffer from deconditioning. Foregoing
research has led to the recognition of patients with the
so-called post-PE syndrome (PPS), defined as new or
progressive dyspnea, exercise intolerance, and/or dimin-
ished functional status following PE without an apparent
non-PE alternative explanation [8]. Guidelines provide
clear recommendations for the management of CTEPH,
the most severe presentation of PPS affecting about 4%
of the patients following PE [2]. Studies focusing on ad-
equate treatment of other PPS presentations to improve
functionality and decrease symptoms are, however, lack-
ing and guidelines make no mention of this large patient
group. Because it is likely that physical deconditioning
may be responsible for at least a part of the disease bur-
den, it has been hypothesized that patients with PPS
may benefit from pulmonary rehabilitation [7, 9].
Pulmonary rehabilitation is a core component in the
management of chronic lung disease and is mostly uti-
lized by patients with chronic obstructive pulmonary
disease (COPD). Programs typically consist of patient-
tailored therapies such as exercise training, education,
and behavioral changes, based on a thorough assessment
of the patient, with the goal of improving physical and
psychological condition and promoting long-term adher-
ence to health-enhancing behaviors [10]. Rehabilitation
is a cost-effective intervention and has demonstrated a
reduction in respiratory symptoms such as the percep-
tion of dyspnea, improved physical function and HRQoL
in patients with COPD, and reducing hospital admis-
sions and improving mortality rates [10]. Recently, there
has been an increased focus on the benefits of rehabilita-
tion for other types of patients experiencing similar re-
spiratory symptoms and reduced exercise capacity, such
as lung cancer, pulmonary hypertension, and cystic fi-
brosis [10]. Moreover, a study from 2016 investigated
the feasibility of a breathlessness rehabilitation program
for patients with both respiratory and cardiac disease
suggesting that rehabilitation should focus on the symp-
toms and limitations that patients experience rather than
traditional disease-focused rehabilitation [11].
To our knowledge, there are few studies that have ad-
dressed the effect and safety of rehabilitation and exer-
cise after PE or DVT. One retrospective study evaluated
the safety of rehabilitation after PE, showing that it is
safe to start to exercise following PE [12]. One small
randomized controlled trial (RCT) objectively measured
the effect of exercise and behavioral weight loss after
VTE demonstrating that early initiation of exercise was
safe and resulted in improvements in physical activity
and fitness [13]. Both studies pointed out the need for
large prospective RCTs. Furthermore, a recently com-
pleted study randomized patients with newly diagnosed
PE, regardless of the presence of persistent dyspnea, to a
home-based training program or a control group [14].
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This study concluded that home-based exercise training
and nurse consultations did not improve exercise cap-
acity or symptoms of dyspnea following PE. However,
this study included all PE patients, rather than those
with PPS only, thus including patients who had recently
been diagnosed with PE where a spontaneous improve-
ment in symptoms can be expected from the natural
course of the disease. No current studies have provided
rehabilitation to patients suffering with PPS. Previous re-
search has indicated that the HRQoL impairment in pa-
tients with PPS is driven by reduced physical capacity
[4] suggesting a possible receptivity for an intervention
such as pulmonary rehabilitation, including exercise
training, in order to reduce breathing discomfort and
improve HRQoL and exercise capacity.
The aim of this study is to explore the effect of pul-
monary rehabilitation on exercise capacity, dyspnea, and
HRQoL in patients with PPS.
Hypothesis
The primary hypothesis is that a structured, outpatient,
hospital-based, 8-week pulmonary rehabilitation pro-
gram will lead to increased exercise capacity, less symp-
toms of dyspnea, and improvements in HRQoL in
patients with PPS as compared to a control group re-
ceiving no active intervention.
Methods and design
Study design
A two-center RCT is being performed at the outpatient
departments of Østfold Hospital Trust (ØHT) and Aker-
shus University Hospital (AHUS) in Norway. Patients
with PPS are 1:1 randomized into two arms, an interven-
tion arm and a control arm, using sealed envelopes. The
allocation sequence will be computer generated, and to
ensure balanced recruitment during the study, this will
be performed in blocks of 10. The allocation sequence
will not be available to the person enrolling participants
and the randomization code will be kept inside sealed
opaque envelopes. The generation of the allocation se-
quence has been performed by the statistician at ØHT.
The enrollment process and assignment of interventions
will be performed by the PhD candidates.
In addition, a group of patients with no PPS following
PE will be examined at baseline to compare patients
with and without persistent dyspnea after PE in terms of
exercise capacity, daily physical activity, dyspnea, and
HRQoL.
The primary study objective is to explore the short-
term changes in exercise capacity from baseline to 12
weeks after inclusion between groups as measured by
the incremental shuttle walk test (ISWT). The secondary
objectives are to explore the long-term effect of the re-
habilitation program on exercise capacity 36 weeks after
inclusion between groups (ISWT) as well as changes in
exercise endurance (ESWT), subjective symptoms of
dyspnea, daily physical activity levels, and HRQoL from
baseline to 12 and 36 weeks after inclusion.
Eligibility criteria
Patients diagnosed and treated for PE 6months to 6
years previously at ØHT or AHUS are identified from
ØHT’s Thrombosis registry (TROLL registry—NSD
28435/3/LMR) (ØHT only) or via ICD-10 discharge
codes (AHUS). Patients are invited to participate by pos-
tal mail.
Inclusion criteria include age 18–75 years, objectively
diagnosed symptomatic PE (greater than isolated sub-
segmental PE) by CTPA 6months to 6 years prior to in-
clusion to the study, persistent dyspnea defined as modi-
fied Medical Research Council (mMRC) breathlessness
scale grade ≥ 1 that had appeared or worsened after the
diagnosis of PE, and the ability to provide written in-
formed consent.
Exclusion criteria include pulmonary diseases (such as
COPD GOLD ≥ 2 or restrictive pulmonary diseases, lung
cancer, or pleural disease), heart failure, CTEPH, signifi-
cant valvular heart disease, patients with a condition that
would interfere with the ability to comply with the study
protocol or to give informed consent (e.g., history of drug
abuse, excessive alcohol beverage consumption, cognitive
dysfunction, or severe psychiatric disease), active malig-
nancy or recurrent, metastatic or inoperable disease, life
expectancy less than 3months, and pregnancy.
Blinding
The investigators performing the walking tests at follow-
up are blinded to the patients’ group allocation. Due to
the nature of the intervention, blinding of the partici-
pants and the physiotherapists providing the interven-
tion is not possible. The statistician who will perform
the data analysis will be blind to group allocation.
Intervention
Rehabilitation group
Patients in the intervention group are allocated to a
basic pulmonary rehabilitation program consisting of a
supervised, outpatient exercise program for 1 h twice
weekly for 8 weeks. Experienced physiotherapists con-
struct an individually adapted exercise program based
on existing pulmonary rehabilitation programs (combin-
ing relaxation, interval training at moderate intensity
measured with the Borg scale, and resistance training),
and an educational session provided by a medical doctor
and a physiotherapist. The educational session includes
topics, such as normal anatomy and physiology of the
respiratory and circulatory system, information on PE
and PPS, breathing strategies, and benefits of exercise/
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physical activity. Training attendance is documented and
patients will be given a simple home-based exercise pro-
gram, consisting of resistance exercises that can be per-
formed without equipment, to be performed once to
twice weekly during the intervention period. Implement-
ing supervised, outpatient rehabilitation program will
not require alteration to all other usual care pathways
(including use of any medication in particular anticoagu-
lation) and these will continue for both trial arms. Min-
imal actions will be made to improve adherence, for
example only one telephone call will be made in the case
of poor attendance.
Control group
Patients randomized to the control group will receive
usual care without specific instructions to exercise (no ac-
tive intervention). All patients were treated and followed
up according to international guidelines [15]. The partici-
pants randomized to standard care in the control group
will not receive any structured exercise or information as
part of the current study, but continue their routine
follow-up at the outpatient clinic. However, if they already
perform regular physical activity at the time of inclusion,
they are encouraged to continue doing so.
Outcome measures
Primary outcome measure
The primary endpoint of the study is improvement in
physical capacity as measured by the ISWT. This walk-
ing test has been developed to assess exercise capacity
and is valid, reliable, and responsive in a number of
study populations, including patients with cardiac and
respiratory diseases [16]. The patient walks between two
shuttles along a 9-m track in a tempo guided by audible
sounds which increase in speed every minute for a max-
imum of 12 min. The test ends when the patient cannot
manage to keep the correct speed or has to stop because
of symptoms (such as dyspnea or fatigue). Standardized
instructions will be provided before the test commences.
In order to exclude a learning effect, the ISWT is per-
formed twice at baseline with at least 15 min between
tests. Peripheral oxygen saturation is registered and pa-
tients will report their subjective experience of dyspnea
during exertion using the Borg scale before and immedi-
ately after the test [17]. The Borg scale is commonly
used for assessing perceived exertion during field walk
tests. The minimal clinical important difference (MCID)
for the ISWT is 70 m in patients with cardiac disease
and 48m in patients with COPD [18, 19].
Secondary outcome measures
Endurance shuttle walk test The endurance shuttle
walk test (ESWT) is a derivative of the ISWT. The
patient walks between two shuttles along a 9-m track at
a predefined speed, usually at 85% of the maximum
speed derived from the ISWT. The test ends when the
patient cannot continue because of symptoms (such as
dyspnea or fatigue) or for a maximum of 20min (test
completion). The outcome of the ESWT is usually re-
ported as time (minutes and seconds), although in some
studies the distance completed (meters) has been used.
Studies suggest that the ESWT is more sensitive to
change after rehabilitation when compared to the
6MWT and ISWT [20, 21]. However, compared to our
primary endpoint (ISWT), there is less evidence on
using the ESWT and there are no reference values for
the PPS population. The MCID for the ESWT has been
demonstrated to be 174 to 279 s in COPD after pulmon-
ary rehabilitation [22].
Modified MRC dyspnea scale The mMRC scale is a
widely used tool for evaluating the limitation of activities
due to dyspnea. This short questionnaire consists of five
statements describing the patient’s respiratory disability,
ranging from 0 (“not troubled by breathlessness except
on strenuous exercise”) to 4 (“too breathless to leave the
house or breathless when dressing or undressing”). The
MCID for the mMRC is 0.5 points [23].
The Shortness of Breath Questionnaire The Shortness
of Breath Questionnaire (SOBQ) is a patient-reported
outcome measure which assesses subjective symptoms
of dyspnea associated with activities of daily living
(ADL). The SOBQ includes 24 items and each is scored
on a scale from 0 (“not at all”) to 5 (“maximal/unable to
do because of breathlessness”). Total scores range from
0 to 120 with a higher score indicating a higher degree
of dyspnea.
Sensewear activity monitor Daily physical activity is
measured using a Sensewear activity monitor. The par-
ticipants will wear the monitor for 1 week before and 1
week after the intervention period to investigate whether
the intervention results in a change in daily physical ac-
tivity or not by measuring the number of steps taken per
day and time spent in different activity intensities. Sense-
wear is a multisensor activity monitor combining a tri-
axial accelerometer and is shown to be a reliable and
valid tool for measuring physical activity in people with
respiratory disease [24, 25].
EQ-5D-5L The EQ-5D-5L has been developed by the
Euroqol Group as a patient-reported outcome measure
to assess generic health status and HRQoL in 5 different
dimensions: mobility, self-care, usual activities, pain/dis-
comfort, and anxiety/depression. Each dimension has 5
possible answers ranging from 1 to 5 with a higher score
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indicating worse possible state, and these scores can be
aggregated to a utility score on a 0–1 scale using a tariff
of preferences derived from a general population [26]. In
addition, the patient subjectively scores their general
HRQoL on a visual analogue scale from 0 (“worst im-
aginable state of health”) to 100 (“best imaginable state
of health”).
Pulmonary Embolism Quality of Life Questionnaire
The Pulmonary Embolism Quality of Life Questionnaire
(PEmb-QoL) is a disease-specific patient-reported out-
come measure to assess HRQoL following PE [27]. The
PEmb-QoL has 40 items over 6 domains, which assess
symptom frequency, the time of day when complaints
are at their worst, and the effect of pulmonary-specific
symptoms on ADL and work-related problems. Scores
for each domain range from 0 to 100 with the average
score of all six domains being used to calculate the total
score. A lower score indicates better HRQoL. The MCID
for the PEmb-QoL is 15 points [28].
The Hospital Anxiety and Depression Scale The Hos-
pital Anxiety and Depression Scale (HADS) is a
patient-reported outcome measure assessing symptoms
of depression and anxiety. The HADS provides a total
score with a 0–42 range with a higher score indicating
that the patient is more symptomatic. Scores of ≥ 19
points indicate symptoms corresponding to cases of
anxiety and depression, whilst scores between 15 and
18 points suggest possible symptoms of anxiety and de-
pression. It is also possible to calculate a score for anx-
iety or depression only (range 0–21 points). Scores of ≥
11 points indicate symptoms that can be compatible
with anxiety/depression, and 8–10 points suggest pos-
sible symptoms of anxiety/depression. The MCID for
the HADS has been suggested to be a reduction of 1.3
to 1.8 points in COPD patients undergoing pulmonary
rehabilitation [29].
Data collection
All outcome measures are completed at baseline and 12
and 36 weeks after inclusion (Figs. 1 and 2). In addition,
a complete baseline evaluation is performed on all par-
ticipants including a full history and medical examin-
ation, routine blood tests and biobanking (10 ml EDTA
plasma, 10 ml citrated plasma, 10 ml serum, and 10 ml
in paxgene), ventilation and perfusion scintigraphy,
pulmonary function test (including spirometry, whole
body plethysmography, carbon monoxide diffusing cap-
acity of the lung), and transthoracic echocardiography.
In addition, cardiac magnetic resonance imaging is per-
formed on 50 participants without PPS and 50 partici-
pants with PPS before and after rehabilitation. Finally,
patients will be asked to complete questions on self-
reported physical activity and exercise habits.
Data collected during the course of the research will
be kept strictly confidential and will be stored in the se-
cure research server at ØHT to which only the project
investigators have access. Participants will be allocated
an individual trial identification number and only de-
identified data will be analyzed. The identification key
will be stored in a separate file on the secure research
server. Only the project investigators and the statistician
analyzing the data will have access to the data set. Anon-
ymized data may be shared with other researchers to en-
able international prospective meta-analyses.
Data management and analysis
The results will be analyzed according to the intention-
to-treat principle. Baseline characteristics will be de-
scribed by mean and standard deviation, median and
interquartile range, or number and proportions as ap-
propriate. The effect of the intervention on the primary
outcome (ISWT) will be assessed by comparing the
change in exercise capacity after 12 weeks. The primary
analysis based on the baseline data and data after 12
weeks will be conducted as a linear regression. The sub-
sequent analysis, which will include data after 36 weeks,
Fig. 1 Study design
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will have three measurements per individual to assess
the short-term and long-term effect of the intervention
and will therefore be analyzed using a linear mixed
model. This variant of multiple linear regression allows
for addressing such correlations as well as adjusting for
possible confounders such as age, body mass index, sex,
and treatment center. HRQoL, general activity, and the
mMRC breathlessness scale will be compared between
the 2 groups at 12 weeks using appropriate statistical
tests depending on the normality of data. In addition,
the model will also account for missing values. We will
apply a post hoc sensitivity analysis to get an indication
on potential bias caused by comparing potentially un-
equal groups with respect to time since PE at the time
of inclusion. One way to achieve this is by the use of re-
sampling techniques.
Sample size calculation
There is currently no data on the physical capacity of
PPS patients as measured by ISWT. Therefore, in con-
currence with the Danish study that was ongoing when
we designed our protocol [30], we have based our sam-
ple size calculations on the mean improvement in ISWT
previously reported in patients with cardiac and respira-
tory disease. Rolving et al. assumed that the achieved dif-
ference will be around 70 m, i.e., comparable to cardiac
patients. Based on 6MWT results from a previous study
in patients with PPS [6], patients walked between 413
Fig. 2 Schedule of enrolment, interventions, and assessments
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and 480 m on 6MWT, which is closer to the cardiac
population. Therefore, we assume a baseline ISWT for
PE patients to be 390m.
Based on calculations, our clinical experience, and on
previous findings, an improvement of 60 m or more on
the ISWT will be considered as being of clinical rele-
vance. Given these assumptions, a required sample size
to test for that effect size with a type 1 error of 5% and a
type 2 error of 20%, 86 patients are needed in each study
arm. By adding 10% attrition, the required sample size
will be a total of 190 patients. No interim analysis will
be performed.
Discussion
This study is understood to be the first study exploring
the effect of structured pulmonary rehabilitation on ex-
ercise capacity in patients with PPS. Results from this
study may therefore increase the knowledge regarding
the management of persistent dyspnea in this patient
group as well as providing a currently untreated group
of patients with a treatment potentially resulting in re-
duced chronic symptoms following PE. In comparison to
previous studies, patients with chronic, persistent dys-
pnea from 6 months post-PE are included in the present
study in whom no spontaneous improvement may be ex-
pected. The ISWT is validated, commonly used in clin-
ical practice, and was the chosen primary outcome for
the study by Rolving et al. [30]. Thus, the ISWT was
chosen as the primary endpoint in the present study to
enable generalization to clinical practice as well as com-
parison to the findings by Rolving et al.
The definition of PPS is somewhat unclear and several
different definitions have been used in previous studies.
The study group has chosen to identify PPS patients
based on the presence of subjective symptoms of persist-
ent dyspnea, which started or was worsened at the time
of PE diagnosis, compared to other studies who have de-
fined PPS as the presence of dyspnea and/or reduced
functional capacity and/or reduced HRQoL.
The main inclusion criterion is the presence of a PE
event within a period of 6 months to 6 years. Although
this timeframe may be considered to be wide, and may
potentially result in heterogeneity in the sample popula-
tion, the study group considered it important that the
time since PE should be long enough to prevent the oc-
currence of spontaneous improvements in dyspnea and
physical function following PE as described by Kahn
et al. [7]. Our previous research has shown that patients
may present with symptoms of dyspnea many years fol-
lowing an acute PE episode; thus, we did not want to
deny patients with long standing dyspnea a therapeutic
option that may improve their complaint. Further, based
on our experience and current research on the effect of
pulmonary rehabilitation on patients with chronic
dyspnea, the study group chose to include patients with
more chronic symptoms as well as those who had suf-
fered with PE relatively recently in order to explore any
potential differences in treatment effect between patients
with recent PE or more chronic symptoms. In addition,
the majority of the participants will be recruited from
the ØHT’s Thrombosis registry where few patients will
have experienced a PE more than 2 years prior to re-
cruitment; thus, the mean time since PE will be shorter.
Results from this study may have clinical significance
by increasing the understanding of the background, as-
sessment, treatment, and prevention of PPS and may
change treatment standards in this patient group. The
study may also increase the awareness of pulmonary re-
habilitation being a feasible treatment for patients with
respiratory symptoms similar to COPD and other well-
documented respiratory diseases.
Data monitoring
The study will be monitored by the research department
at ØHT. Any adverse effects will be reported. The trial
steering committee is made up of the supervisors of the
three PhD candidates and a selection of experts within
the field of PE. The role of the steering committee is to
ensure the quality of the trial and sufficient progress un-
derway. The trial steering committee will meet twice a
year to review the progress of the study and address po-
tential challenges and obstacles during the course of the
trial. The PhD candidates are responsible for setting up
the committee meetings. The group providing day to
day support for the progression of the trial is made up
of the PhD candidates and their main supervisors, as
well as research nurses and research advisors at ØHT
who ensure the performance of the trial and practical
tasks such as testing patients following intervention
(blind to randomization). The PhD candidates are re-
sponsible for all aspects of local organization including
identifying potential recruits and collecting informed
consent. The PhD supervisors and advisors at the re-
search department at ØHT are responsible for supervis-
ing the trial and meet regularly. As this trial does not
involve any use of pharmaceutical drug or medical de-
vice, no formal safety and monitoring board has been
established. However, the conduct and progress of the
study will be regularly overseen by the leader of the
group, professor Waleed Ghanima.
Trial status
The trial is currently ongoing and recruitment began in
January 2018 at ØHT and in August 2019 at AHUS. Re-
cruitment is expected to be complete in late 2020 to
early 2021.
Protocol version 1 (original protocol September 2017).
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